Prognostic ¹⁸F-flotufolastat PET parameters for outcome assessment of ¹⁷⁷Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer.

ABSTRACT:

Purpose

This retrospective analysis evaluates baseline ¹⁸F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [¹⁷⁷Lu]Lu-PSMA-I&T.

Methods

A total of 188 mCRPC patients with baseline ¹⁸F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics. Outcome measures included prostate-specific antigen (PSA) response, PSA-progression-free survival (PSA-PFS), and overall survival (OS). Univariate and multivariate regression analyses assessed the impact of basel

SUBMITTER: Karimzadeh A 

PROVIDER: S-EPMC12014739 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature